Athersys pivots stem cell therapy to Covid-19, but prior data raise questions

Athersys pivots stem cell therapy to Covid-19, but prior data raise questions

STAT Plus: Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence

By ADAM FEUERSTEIN

LUCAS BARIOULET/AFP VIA GETTY IMAGES

When Athersys pivoted to Covid-19, its market value jumped to nearly $600 million. That's unjustified, given questions about its stem cell treatment.

READ MORE